When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities
They are intended to complement a broader wellness routine and are not designed to diagnose, treat, cure or prevent any disease
When initiating GLP-1 therapy, patients should assess their current fibre intake before making significant dietary changes
Vitamin B-Complex IV Therapy Vitamin B-Complex IV wellness treatment provides essential B vitamins that are crucial for energy production, nervous system health, and stress management
This separates it from peptide-based research compounds such as Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide
